Study characteristics |
Methods |
Randomized controlled trial |
Participants |
Adults (aged 18 to 65 years) with active ulcerative colitis (N = 135) |
Interventions |
Olsalazine 3 g/day (n = 105) or SASP 4 g/day (n = 30) |
Outcomes |
Clinical improvement and adverse events |
Notes |
Funding support and conflicts of interest were not reported |
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Random sequence generation (selection bias) |
Unclear risk |
Not described |
Allocation concealment (selection bias) |
Unclear risk |
Not described |
Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Not described |
Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Not described |
Selective reporting (reporting bias) |
Unclear risk |
Not described |
Other bias |
Unclear risk |
Not described |